|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0102 USD | -7.27% |
|
-37.04% | -83.78% |
| 05-24 | Roche, LumiraDx Deal Probed by U.K. Competition Watchdog | DJ |
| 05-20 | U.K. Competition Watchdog Weighs Potential Impact of Roche-LumiraDx | DJ |
LumiraDx Limited reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was USD 254.48 million compared to USD 421.43 million a year ago. Net loss was USD 449.38 million compared to USD 100.93 million a year ago.
Basic loss per share from continuing operations was USD 1.59 compared to USD 0.62 a year ago. Diluted loss per share from continuing operations was USD 1.59 compared to USD 0.62 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -83.78% | 3.95M | |
| +8.46% | 220B | |
| +14.38% | 194B | |
| +26.90% | 149B | |
| +33.90% | 113B | |
| +4.45% | 65.75B | |
| +15.11% | 52.43B | |
| +1.93% | 50.47B | |
| -4.22% | 38.54B | |
| -1.75% | 34.12B |
LUMIRADX LIMITED 
